For the year ending 2025-12-31, FBRX had $54,713K increase in cash & cash equivalents over the period. -$50,998K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -69,375 |
| Depreciation expense | 64 |
| Accretion of debt discount on available-for-sale securities | 237 |
| Stock-based compensation expense | 6,258 |
| Prepaid expenses and other assets | 2,574 |
| Accounts payable | 5,543 |
| Accrued liabilities | 8,402 |
| Income taxes payable | 1,037 |
| Net cash used in operating activities | -50,882 |
| Purchase of available-for-sale securities | 0 |
| Proceeds from redemptions of short-term investments | 36,350 |
| Purchase of property and equipment | 116 |
| Net cash provided by (used in) investing activities | 36,234 |
| Proceeds from issuance of common stock and pre-funded warrants | 75,000 |
| Payment of issuance costs associated with financings | 7,441 |
| Proceeds from issuance of common stock upon exercise of underwriters' option | 1,779 |
| Proceeds from issuance of common stock under espp | 18 |
| Proceeds from exercise of warrants and options | 34 |
| Taxes paid related to net share settlement of equity awards | 29 |
| Settlement of fractional shares paid in cash | 0 |
| Net cash provided by financing activities | 69,361 |
| Net increase (decrease) in cash and cash equivalents | 54,713 |
| Cash and cash equivalents - beginning of year | 22,244 |
| Cash and cash equivalents - end of year | 76,957 |
Forte Biosciences, Inc. (FBRX)
Forte Biosciences, Inc. (FBRX)